Cite
HARVARD Citation
van de Putte, L. et al. (2003). Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of the rheumatic diseases. 62 (12), pp. 1168-1177. [Online].